JLE

Hématologie

MENU

Score LLC IPS-E : un nouvel outil pratique pour la surveillance des patients avec une leucémie lymphoïde chronique de stade précoce Volume 26, numéro 4, Juillet-Août 2020

  • [1] Hallek M., Cheson B.D., Catovsky D. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745-2760.
  • [2] Hoechstetter M.A., Busch R., Eichhorst R. Early, risk-Adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group. Leukemia. 2017;31:2833-2837.
  • [3] Dighiero G., Maloum K., Desablens B. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. NEJM. 1998;338:1506-1514.
  • [4] Condoluci A., Terzi Di Bergamo L., Langerbeins P. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135:1859-1869.
  • [5] Zenz T., Eichhorst B., Busch R. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473-4479.
  • [6] Rossi D., Cerri M., Deambrogi C. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15:995-1004.
  • [7] Langerbeins P., Bahlo J., Rhein C. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol. 2015;11:1895-1903.